knowledge -WSS

knowledge

author：entertainment 2025-09-06 08:03:51 - browse：62

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

focus

WSS

Carvykti CAR

Virtual care provider acquires bankrupt Pear's prescription apps

Despite FDA concern, risk that CAR

Carvykti CAR

J&J to emphasize cancer drugs, stop much of its vaccine research

Virtual care provider acquires bankrupt Pear's prescription apps

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

CRISPR gene editing developments we’re watching in 2024

Peter Hotez and the public health issue of online harassment

U.K. Biobank has 500,000 peoples' genome sequences available

Virginia high school admissions case could be legal follow

SNAP should offer more nutrition education

Jerome Adams on the need for new antivirals for Covid

Why health care costs have stayed mostly flat since 2010

Bright Health sells Medicare Advantage business to Molina

How to pay for weight loss drugs and save Medicare

entertainment

SEC charges former device maker CEO with $41 million fraud

Prime Medicine, Myeloid Therapeutics clash over genome

Albert Bourla of Pfizer: worst biopharma CEO of 2023

HCA sued by state AG for quality issues at Mission Health

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

leisure time

focus

focus

entertainment